Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy

Movement Disorders

Volumn 25, Issue 5, 2010, Pages 638-642

  O'Sullivan, Sean S ^a,b   Djamshidian, Atbin ^a,c   Ahmed, Zeshan ^b   Evans, Andrew H ^d   Lawrence, Andrew D ^e   Holton, Janice L ^b   Revesz, Tamas ^b   Lees, Andrew J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Dopamine agonists; Impulse control disorders; Progressive supranuclear palsy

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE; ROPINIROLE; ROTIGOTINE;

AGED; ARTICLE; BALANCE DISORDER; BINGE EATING DISORDER; BRONCHOPNEUMONIA; CASE REPORT; COMPULSION; COMPULSIVE SHOPPING; DAILY LIFE ACTIVITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; FEMALE; GAIT DISORDER; GAZE PARALYSIS; HUMAN; HYPERSEXUALITY; IMPULSIVENESS; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SIDE EFFECT; TREATMENT RESPONSE; VISUAL HALLUCINATION;

AGED; DOPAMINE; DOPAMINE AGENTS; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 77951247795     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22902     Document Type: Article

References (22)

1. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
2. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130 (Pt 6):1566-1576.
3. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257. (Pubitemid 44563838)
4. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-170.
5. Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007;22:590-591.
6. Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007;13:535-536.
7. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-303.
8. Evans AH, Stegeman JR. Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord 2009;24:140-141.
9. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386.
10. McKeon A, Josephs KA, Klos KJ, et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2007;13:516-519.
11. Kim YY, Park HY, Kim JM, Kim KW. Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 2008;20:496-497.
12. Leu-Semenescu S, Karroum E, Brion A, Konofal E, Arnulf I. Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Med 2009;10:494-496.
13. Salas RE, Allen RP, Earley CJ, Gamaldo CE. Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. Mov Disord 2009;24:627-628.
14. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(Pt 4):861-870.
15. Cordato NJ, Halliday GM, Caine D, Morris JG. Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson's disease. Mov Disord 2006;21:632-638.
16. Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 2009;24:899-905.
17. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007;64:212-216.
18. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757-1763.
19. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008;14:28-32.
20. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
21. Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985;18:523-529.
22. Warren NM, Piggott MA, Greally E, Lake M, Lees AJ, Burn DJ. Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Mov Disord 2007;22:1594-1600.